Latest news with #Microcyn
Business Insider
3 days ago
- Business
- Business Insider
Why Is Sonoma Pharmaceuticals Stock (SNOA) Up 105% Today?
Sonoma Pharmaceuticals (SNOA) stock underwent a massive rally on Thursday after its hypochlorous acid-based diaper cream for infants and children was launched at large retailers in the U.S. According to the company, this includes 3,600 Walmart (WMT) stores, Amazon (AMZN), and certain U.S. grocery chains. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Amy Trombly, CEO of Sonoma, said, 'We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels. We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations.' Sonoma Pharmaceuticals stock was up 103.8% in pre-market trading on Thursday, following a 1.73% rally yesterday. The shares were also up 13.46% year-to-date but have fallen 35.04% over the past 12 months. Today's news brought heavy trading to SNOA stock, with some 42 million shares traded, compared to a three-month daily average of about 84,000 units. Is Sonoma Pharmaceuticals Stock a Buy, Sell, or Hold? Turning to Wall Street, coverage of Sonoma Pharmaceuticals is lacking. Fortunately, TipRanks AI analyst Spark has it covered. Spark rates SNOA stock a Neutral (46) with a $3 price target. It cites 'poor financial performance characterized by declining revenues and negative cash flows' as reasons for this stance.
Yahoo
4 days ago
- Business
- Yahoo
Sonoma Pharmaceuticals Soars 95% After Walmart, Amazon Retail Debut
Aug 14 - Sonoma Pharmaceuticals (NASDAQ:SNOA) saw its stock skyrocket on Thursday morning, gaining nearly 95% after the company's first U.S. over-the-counter product hit major retail shelves. The hypochlorous acid-based diaper cream for infants and children is now available in 3,600 Walmart (NYSE:WMT) stores, on Amazon (NASDAQ:AMZN), and at select U.S. grocery chains. Warning! GuruFocus has detected 7 Warning Signs with SNOA. CEO Amy Trombly said this launch marks an important milestone in Sonoma's retail strategy. We are excited to see our strategy of expanding into the over-the-counter space begin to take hold, she noted, adding that the company aims to make its Microcyn technology widely accessible for parents looking for safe and effective solutions for diaper rash and other skin irritations. The market reaction was immediate. SNOA stock jumped as much as 95% building on a modest 1.7% gain the previous day. Year-to-date, shares are up 13.46%, though they remain down 35.04% over the past 12 months. Trading volume surged to 42 million shares, far exceeding the three-month daily average of about 84,000. With this retail rollout, Sonoma is betting that broader distribution and consumer visibility can help reverse its longer-term stock slump and accelerate its push into the consumer health space. This article first appeared on GuruFocus.
Yahoo
4 days ago
- Business
- Yahoo
Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
BOULDER, CO / / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its HOCl-based diaper rash product for infants and children into large retailers in the United States. The antimicrobial hydrogel is being marketed and sold through Sonoma's U.S.-based distribution partner. The diaper rash product is currently carried in 3,600 Walmart stores, and certain large grocery chains. "We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels," said Amy Trombly, CEO of Sonoma. "We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations." About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Website: us on LinkedIn: us on Instagram: us on Facebook: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire
Yahoo
22-04-2025
- Business
- Yahoo
Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
BOULDER, CO / / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) to be sold through a prominent U.K. health and beauty retailer and pharmacy chain across more than 1,200 stores throughout the United Kingdom. The innovative product line includes an acne toner and a balancing serum, both of which are available under the retailer's own brand name. "We are excited to bring our safe and effective acne line to consumers in the United Kingdom and to expand our range of distribution in Europe," said Amy Trombly, CEO of Sonoma. "These products utilize all-natural hypochlorous acid and our patented Microcyn technology formulation, providing a safe and gentle alternative to products containing harsh ingredients such as alcohol and benzoyl peroxide." About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Website: us on LinkedIn: us on Instagram: us on Facebook: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire
Yahoo
05-02-2025
- Business
- Yahoo
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
Revenues increased 14% for the quarter compared to prior year and 13% year-to-date Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024 Year-to-date net loss decline of $1.1 million BOULDER, CO / / February 5, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended December 31, 2024. "We are pleased to report another strong quarter with increased revenues, positive cash flow from operations, and operating expenses remaining flat in an inflationary period," remarked Amy Trombly, CEO of Sonoma. "We have also announced significant new business developments which we believe will lead to continued growth for our company. These developments include the establishment of new partnerships with Medline Industries, LP and WellSpring Pharmaceutical Corporation, both of which are expected to expand our U.S. sales in 2025." Business Highlights Sonoma continued to grow its distribution network by entering into new partnerships, improving and expanding its regulatory approvals, and expanding its product offerings: On January 29, 2025, Sonoma entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation, a consumer healthcare company with established brands including Bactine, Bonine and Emetrol, for the sale of its Microcyn technology-based products to large retailers in the United States. In January 2025, Sonoma's distributor for dermatology products in Ukraine received marketing approval and placed its initial order for GramaDerm® acne treatment, Epicyn® scar gel, and Pediacyn®. On December 9, 2024, Sonoma relaunched direct sales of its prescription dermatology and eye care products lines, which were previously sold through a distributor, including Acuicyn® Eyelid & Eyelash Hygiene, Epicyn Facial Cleanser, Levicyn® Dermal Spray and Gels, and Celacyn® Scar Management Gel, as well as Lasercyn®Dermal Spray and Gel for over-the-counter use. On November 8, 2024, Sonoma received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based hydrogel, which included improved biocompatibility and extended shelf life. Sonoma also announced that it had successfully completed transition to the new European Union (EU) Medical Device Regulation (MDR) for four of its products in Europe, receiving classification as a Class IIb medical device for Microdacyn60® Wound Care and Microdacyn60 Hydrogel, its scar gel product Epicyn, and Pediacyn for atopic dermatitis. On October 17, 2024, Sonoma entered into an amendment to its distribution agreement with Medline Industries, LP for the marketing and distribution of its wound care products to allow for the marketing and distribution of its wound care products in Canada as well as the United States, and to add over-the-counter wound care products for sale in both countries. Results for the Quarter Ended December 31, 2024 Revenues for the quarter ended December 31, 2024 of $3.6 million increased by $0.5 million, or 14%, compared to $3.1 million for the same period last year. Sales in all regions, except the U.S., increased due to increased demand for Sonoma's products. U.S. sales decreased 29%, primarily due to a decrease in demand for consumer-focused animal health care products. For the quarter ended December 31, 2024, Sonoma reported revenues of approximately $3.6 million and cost of revenues of $2.3 million, resulting in gross profit of $1.3 million, or 36% of revenue, compared to a gross profit of $1.5 million, or 47% of revenue, for the same period last year. Gross margins decreased by 11% for the quarter ended December 31, 2024 when compared to the same period last year as a result of prior period utilization of manufacturing resources to support new regulatory requirements in Europe, which were reported within research and development expense. Total operating expenses during the quarter ended December 31, 2024 were $2.3 million, approximately flat when compared to $2.3 million during the same period in the prior year. Net loss before income taxes for the quarter was $0.9 million, compared to $0.9 million for the same period last year. EBITDA loss for the quarter ended December 31, 2024 of $1.0 million increased by $0.3 million, compared to an EBITDA loss of $0.7 million for the same period last year. Results for the Nine Months Ended December 31, 2024 Revenues of $10.5 million for the nine months ended December 31, 2024 increased by $1.2 million, or 13%, compared to $9.3 million for the same period last year. Sales in all regions except the U.S. and Rest of World increased due to increased demand for Sonoma's products. For the nine months ended December 31, 2024, Sonoma reported revenues of $10.5 million and cost of revenues of $6.6 million, resulting in gross profit of $3.9 million, or 37% of revenues, compared to a gross profit of $3.7 million, or 39% or revenues, in the same period last year. Total operating expenses during the nine months ended December 31, 2024 of $7.0 million increased by $0.1 million, or 1%, compared to $6.9 million during the same period last year. Net loss before income taxes for the nine months ended December 31, 2024 was $2.4 million, compared to $3.7 million for the same period in the prior year. EBITDA loss for the nine months ended December 31, 2024 of $2.8 million increased by $0.1 million, compared to an EBITDA loss of $2.7 million for the same period last year. About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™, Microcyn®, GramaDerm®, Pediacyn®, Acuicyn®, Epicyn®, Levicyn®, Celacyn®, Lasercyn® and Microdacyn60® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Website: Follow us on LinkedIn: Follow us on Instagram: Follow us on Facebook: SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets(In thousands, except share amounts) December 31, 2024 March 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 5,236 $ 3,128 Accounts receivable, net 2,405 2,898 Inventories, net 3,143 2,719 Prepaid expenses and other current assets 1,387 3,541 Current portion of deferred consideration, net of discount 209 262 Total current assets 12,380 12,548 Property and equipment, net 215 365 Operating lease, right of use assets 119 286 Deferred tax asset 760 1,145 Deferred consideration, net of discount, less current portion 121 330 Other assets 73 66 Total assets $ 13,668 $ 14,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,395 $ 607 Accrued expenses and other current liabilities 1,916 2,113 Deferred revenue, current portion 302 478 Short-term debt - 323 Operating lease liabilities, current portion 90 198 Total current liabilities 3,703 3,719 Deferred revenue, net of current portion 30 87 Withholding tax payable 5,036 4,710 Operating lease liabilities, less current portion 29 87 Total liabilities 8,798 8,603 Commitments and Contingencies Stockholders' Equity: Preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2024 and March 31, 2024, no shares issued and outstanding at December 31, 2024 and March 31, 2024 - - Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at December 31, 2024 and March 31, 2024, respectively, 1,615,765 and 780,371 shares issued and outstanding at December 31, 2024 and March 31, 2024, respectively - - Additional paid-in capital 206,454 203,209 Accumulated deficit (197,030 ) (194,349 ) Accumulated other comprehensive loss (4,554 ) (2,723 ) Total stockholders' equity 4,870 6,137 Total liabilities and stockholders' equity $ 13,668 $ 14,740 SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Comprehensive Loss(In thousands, except per share amounts)(Unaudited) Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues $ 3,564 $ 3,138 $ 10,534 $ 9,296 Cost of revenues 2,294 1,678 6,597 5,642 Gross profit 1,270 1,460 3,937 3,654 Operating expenses: Research and development 427 601 1,403 1,462 Selling, general and administrative 1,874 1,703 5,588 5,484 Total operating expenses 2,301 2,304 6,991 6,946 Loss from operations (1,031 ) (844 ) (3,054 ) (3,292 ) Other income (expense), net 112 (79 ) 675 (380 ) Loss from operations before income taxes (919 ) (923 ) (2,379 ) (3,672 ) Income tax (expense) benefit (9 ) 57 (302 ) (96 ) Net loss $ (928 ) $ (866 ) $ (2,681 ) $ (3,768 ) Net loss per share: basic and diluted $ (0.63 ) $ (1.59 ) $ (2.40 ) $ (10.74 ) Weighted-average number of shares: basic and diluted 1,464 546 1,117 351 Other comprehensive loss: Net loss $ (928 ) $ (866 ) $ (2,681 ) $ (3,768 ) Foreign currency translation adjustments (357 ) 297 (1,831 ) 595 Comprehensive loss $ (1,285 ) $ (569 ) $ (4,512 ) $ (3,173 ) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESRECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES(In thousands)(Unaudited) Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 (1) Loss from operations minus non-cash expenses EBITDA loss: GAAP operating loss as reported $ (1,031 ) $ (844 ) $ (3,054 ) $ (3,292 ) Non-cash adjustments: Stock-based compensation 13 140 134 447 Depreciation and amortization 33 45 107 135 Non-GAAP income (loss) from operations minus non-cash expenses EBITDAS income (loss) $ (985 ) $ (659 ) $ (2,813 $ (2,710 (2) Net loss minus non-cash and one-time expenses: GAAP net income (loss) as reported $ (928 ) $ (866 ) $ (2,681 ) $ (3,768 ) Non-cash adjustments: Stock-based compensation 13 140 134 447 Non-cash foreign exchange transaction losses and other (income) and expense (3 ) 92 (405 421 Income taxes expense (benefit) 9 (57 302 96 Depreciation and amortization 33 45 107 135 Non-GAAP net income (loss) minus non-cash expenses $ (876 ) $ (646 ) $ (2,543 ) $ (2,669 ) (3) Operating expenses minus non-cash expenses GAAP operating expenses as reported $ 2,301 $ 2,304 $ 6,991 $ 6,946 Non-cash adjustments: Stock-based compensation (13 ) (140 (134 ) (447 ) Depreciation and amortization (33 ) (45 ) (107 ) (135 ) Non-GAAP operating expenses minus non-cash expenses $ 2,255 $ 2,119 $ 6,750 $ 6,364 (1) Income (loss) from continuing operations minus non-cash expenses (EBITDA) is a non-GAAP financial measure. The company defines operating income (loss) minus non-cash expenses as GAAP reported operating income (loss) minus operating depreciation and amortization, and operating stock-based compensation. The company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. (2) Net income (loss) minus non-cash and one time expenses is a non-GAAP financial measure. The company defines net income (loss) minus non-cash expenses as GAAP reported net income (loss) minus depreciation and amortization, stock-based compensation, forgiveness of PPP loan and non-cash foreign exchange transaction losses. The company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. (3) Operating expenses minus non-cash expenses is a non-GAAP financial measure. The company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESPRODUCT RELATED REVENUE SCHEDULES(In thousands) (Unaudited) The following table presents the company's disaggregated product revenues by geographic region: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 United States $ 614,000 $ 868,000 $ 1,930,000 $ 2,214,000 Europe 1,257,000 1,217,000 3,943,000 3,488,000 Asia 579,000 522,000 1,832,000 1,730,000 Latin America 829,000 368,000 2,174,000 1,165,000 Rest of the World 285,000 163,000 655,000 699,000 Total $ 3,564,000 $ 3,138,000 $ 10,534,000 $ 9,296,000 SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
